Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cotadutide in non-cirrhotic NASH with fibrosis
NCT05364931Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Apr 2024
- Modality
- Peptides
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of Participants With Adverse Events at 52 weeks, Number of Participants With Abnormal Vital Signs at 52 weeks and 4 more. Started Jul 2022; status: completed.
02
Drugs
cotadutide
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05364931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364931.